The company said, “The Company is reaffirming its full-year 2025 revenue outlook, reflecting confidence in its continued commercial execution and portfolio performance.”
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CPRX:
- Catalyst Pharmaceuticals reports Q1 EPS 68c, consensus 53c
- Catalyst Pharma Reports Record Q1 2025 Financial Results
- CPRX Earnings this Week: How Will it Perform?
- Catalyst Pharmaceuticals price target raised to $34 from $33 at BofA
- Catalyst Pharmaceuticals announces Health Canada’s acceptance of AGAMREE NDS